Composition: Each capsule contains Crizotinib INN 250 mg.
ALK-Positive Metastatic NSCLC: Rizonib is indicated for the treatment of patients with metastatic Non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
ROS1-Positive Metastatic NSCLC: Rizonib is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive.
Dosage and Administration: The recommended dose of Rizonib is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. The recommended dose of Rizonib in patients with severe renal impairment [creatinine clearance (CLcr) < 30>
Use in Pregnancy and Lactation: There are no adequate and well-controlled studies in pregnant women using Crizotinib. Females of reproductive potential should be advised of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Females of reproductive potential should be advised to use effective contraception during treatment with Rizonib and for at least 45 days after the final dose.
Packing: Each box contains 60 capsules in blister pack.